資源描述：
《芪藶強(qiáng)心膠囊治療慢性收縮性心力衰竭臨床療效觀察.doc》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫(kù)。
1、罠茄強(qiáng)心膠囊治療慢性收縮性心力衰竭臨床療效觀察(湖南省邵陽(yáng)市第一人民醫(yī)院心血管內(nèi)科湖南邵陽(yáng)422001)【摘要】目的：研究罠茁強(qiáng)心膠囊在慢性收縮性心力衰竭治療方面的臨床療效及安全性。方法：將我院2013年2月?2014年6月收治的符合心力衰竭研究標(biāo)準(zhǔn)的160例患者隨機(jī)分為罠苗強(qiáng)心膠囊治療組(80例)和常規(guī)心寶丸對(duì)照組(80例)。8周后進(jìn)行超聲心動(dòng)圖、中醫(yī)證候療效、心功能療效等指標(biāo)療效觀察，并針對(duì)牛活質(zhì)量及不良反應(yīng)等指標(biāo)考究其安全性。結(jié)果：(1)心功能療效:對(duì)照組的總有效率為64.2%,治療組總有效率為73.9%,治療組療效明顯優(yōu)于對(duì)照組(PV0.05)。(2)中醫(yī)證
2、候療效：治療組顯效率和總有效率分別為54.8%和79.5%,對(duì)照組分別為37.5%和71.9%,治療組療效明顯優(yōu)于對(duì)照組(P<0.05)。(3)超聲心動(dòng)圖指標(biāo)：兩組LVEF、FS、SV和治療組CO治療后較治療前均升高(P<0.05或P<0?01),治療組LVEF優(yōu)于對(duì)照組(PV0.05)。(4)生活質(zhì)量:治療組對(duì)患者?；钯|(zhì)量的改善顯著優(yōu)于對(duì)照組(P<0.01)o(5)安全性指標(biāo)：兩組均未見異常變化及出現(xiàn)不良反應(yīng)。結(jié)論：罠茁強(qiáng)心膠囊治療慢性收縮性心力衰竭療效不錯(cuò)，H無(wú)明顯不良反應(yīng)，安全性較高?！娟P(guān)鍵詞】心力衰竭；慢性收縮性；罠茁強(qiáng)心膠囊；療效；安全性
3、【中圖分類號(hào)】R573【文獻(xiàn)標(biāo)識(shí)碼】A【文章編號(hào)】1004-6194(2015)02-0456-02【Abstract]Objective:tostudythestilbeneListrongheartcapsuleinthetreatmentofchronicsystolicheartfailureclinicalcurativeeffectandsafety.Methods:ourhospitalinFebruary2013-June2014wereuptothestandardofheartfailureinthe160patientswererandomly
4、dividedintostilbeneListrongheartcapsuletreatmentgroup(80cases)andnormalhearttreasurebolusofthecontrolgroup(80cases)?AftereightweeksofechocardiographyandcurativeeffectofTCMsyndromecurativeeffect,andcardiacfunctionindexofcurativeeffectobservation,andonthequalityoflifeandadversereactionsu
5、chasfastidiousitssafety.Results:(1)thecardiacfunctioneffect:inthecontrolgrouptotaleffectiveratewas64.2%,treatmentgrouptotaleffectiveratewas73.9%,thecurativeeffectoftreatmentgroupwasobviouslybetterthanthatofcontrolgroup(P<0.05).(2)syndromescurativeeffect:thetreatmentgroupsignificante
6、fficiencyandtotaleffectiveratewere54.8%and79.5%respectively,andthecontrolgroupwere37.5%and71.9%respectively,thecurativeeffectoftreatmentgroupwasobviouslybetterthanthatofcontrolgroup(P<0.05).(3)echocardiographyindex:twogroupsofLVEF,FS,SVCOaftertreatmentthanbeforetreatmentandtreatment
7、groupwerehigher(P<0.05orP<0.01),treatmentgroupLVEFisbetterthanthatofcontrolgroup(P<0.05).(4)thequalityoflife:thetreatmentgrouponpatientsqualityoflifeimprovedsignificantlybetterthanthatofcontrolgroup(P<0.01).(5)safetyindicators:therewerenoabnormalchangesinthetwogroupsandap
